Granupas (previously Para-aminosalicylic acid Lucane)


para-aminosalicylic acid

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Granupas. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Granupas.

For practical information about using Granupas, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 26/04/2023

Authorisation details

Product details
Granupas (previously Para-aminosalicylic acid Lucane)
Agency product number
Active substance
Para-aminosalicylic acid
International non-proprietary name (INN) or common name
para-aminosalicylic acid
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Eurocept International B. V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Trapgans 5
1244 RL Ankeveen
The Netherlands

Product information

18/04/2023 Granupas (previously Para-aminosalicylic acid Lucane) - EMEA/H/C/002709 - N/0039

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
3 ratings
1 rating
3 ratings